Pilot Therapeutics Receives Patent for GLA Delivery
WINSTON-SALEM, N.C.--Pilot Therapeutics recently received a patent (No. 6,107,334) from the U.S. Patent and Trademark Office covering its delivery formulation of gamma linolenic acid (GLA) for treating inflammatory disorders.
According to the company, the method delivers both GLA and a delta-5 desaturase inhibitor to minimize GLA's possible increase on serum arachidonic acid. "The patent for our unique formulation of bioactive lipid technologies is a significant milestone in Pilot's development of novel dietary supplements to treat inflammatory and proliferative diseases," said Kenneth Tramposch, Ph.D., executive vice president and chief operating officer. For more information, visit www.pilotp.com.